Welcome to LookChem.com Sign In|Join Free

CAS

  • or

117-89-5

Post Buying Request

117-89-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • trifluoperazine;10-[3-(4-Methylpiperazin-1-yl)propyl]-2-trifluoromethyl-10H-phenothiazine;;10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine;

    Cas No: 117-89-5

  • No Data

  • 1 Metric Ton

  • 5 Metric Ton/Day

  • Hangzhou Sartort Biopharma Co., Ltd
  • Contact Supplier

117-89-5 Usage

Originator

Stelazine,SKF,US,1958

Uses

Different sources of media describe the Uses of 117-89-5 differently. You can refer to the following data:
1. Antipsychotic.
2. 10-[3-(4-Methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine is a psychoactive drug.
3. Trifluoperazine is one of the most active antipsychotic drugs. A moderate stimulatory effect accompanies the neuroleptic effect. Trifluoperazine is unique in that, patients instead of the usual stiffness and weakness characteristic of phenothazine derivatives, become more lively. This drug has a strong anticonvulsant activity. It is widely used in psychiatry for treating schizophrenia and other mental illnesses.

Manufacturing Process

A mixture of 17.2 grams of 2-trifluoromethylphenothiazine, 3.1 grams of sodamide and 14 grams of 1-(3'-chloropropyl)-4-methylpiperazine in 200 ml of xylene is heated at reflux for 2 hours. The salts are extracted into 150 ml of water. The xylene layer is then extracted with several portions of dilute hydrochloric acid. The acid extracts are combined and neutralized with ammonium hydroxide solution. The product, 10-[3'-(4''-methyl-1''- piperazinyl)-propyl]-2-trifluoromethylphenothiazine, is taken into benzene and purified by vacuum distillation, BP 202° to 210°C at 0.6 mm.

Therapeutic Function

Tranquilizer

Clinical Use

Schizophrenia and other psychoses Anxiety Severe nausea and vomiting

Synthesis

Trifluoperazine, 2-trifluoromethyl-10-[3-(4-methyl-1-piperazinyl) propyl]- phenothazine (6.1.5), is synthesized in the manner described above of alkylation using 2- trifluoromethylphenothazin-4-methyl-1-piperazinylpropylchloride [11,17–20].

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone. Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide, dronedarone and amiodarone - avoid with amiodarone and dronedarone. Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin - avoid with moxifloxacin. Antidepressants: increased level of tricyclics; possibly increased risk of antimuscarinic side effects; risk of ventricular arrhythmias with citalopram and escitalopram - avoid; possible increased risk of convulsions with vortioxetine. Antiepileptics: antagonism (convulsive threshold lowered). Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide - avoid; possible increased risk of ventricular arrhythmias with risperidone. Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir - avoid. Anxiolytics and hypnotics: increased sedative effects. Atomoxetine: increased risk of ventricular arrhythmias. Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol. Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide. Diuretics: enhanced hypotensive effect. Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity. Pentamidine: increased risk of ventricular arrhythmias.

Metabolism

Trifluoperazine undergoes extensive first pass metabolism. The major metabolite is the possibly active N-oxide; other metabolites include the sulfoxide and the 7-hydroxy derivative. Elimination occurs in the bile and urine.

Check Digit Verification of cas no

The CAS Registry Mumber 117-89-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 117-89:
(5*1)+(4*1)+(3*7)+(2*8)+(1*9)=55
55 % 10 = 5
So 117-89-5 is a valid CAS Registry Number.
InChI:InChI=1/C21H24F3N3S.2ClH/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24;;/h2-3,5-8,15H,4,9-14H2,1H3;2*1H

117-89-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name trifluoperazine

1.2 Other means of identification

Product number -
Other names Trifluperazine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:117-89-5 SDS

117-89-5Related news

The calmodulin inhibitor and antipsychotic drug Trifluoperazine (cas 117-89-5) inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells09/03/2019

We investigated the effect of the calmodulin inhibitor and antipsychotic drug trifluoperazine on voltage-dependent K+ (Kv) channels. Kv currents were recorded by whole-cell configuration of patch clamp in freshly isolated rabbit coronary arterial smooth muscle cells. The amplitudes of Kv current...detailed

ORIGINAL ARTICLESeparation and determination of Trifluoperazine (cas 117-89-5) and prochlorperazine in pharmaceutical preparations by HPLC09/02/2019

A reverse phase HPLC method is developed for the simultaneous analysis of Trifluoperazine (TFP) and prochlorperazine (PCP) in pharmaceutical preparations. HPLC was carried out on a C18 column using acetonitrile as a mobile phase at 1 mL min−1 flow rate and the effluent was monitored at 250 nm. C...detailed

Original articleMean centering of ratio spectra and successive derivative ratio spectrophotometric methods for determination of isopropamide iodide, Trifluoperazine (cas 117-89-5) hydrochloride and Trifluoperazine (cas 117-89-5) oxidative degradate09/01/2019

Two sensitive, selective and precise stability indicating methods for the determination of isopropamide iodide (ISO), trifluoperazine hydrochloride (TPZ) and trifluoperazine oxidative degradate (DEG) were developed and validated. Method A is a successive derivative ratio spectrophotometric one, ...detailed

Trifluoperazine (cas 117-89-5) blocks the human cardiac sodium channel, Nav1.5, independent of calmodulin08/31/2019

Trifluoperazine is a phenothiazine derivative which is mainly used in the management of schizophrenia and also acts as a calmodulin inhibitor. We used the whole-cell patch-clamp technique to study the effects of trifluoperazine on human Nav1.5 (hNav1.5) currents expressed in HEK293 cells. The 50...detailed

Block of Kv4.3 potassium channel by Trifluoperazine (cas 117-89-5) independent of CaMKII08/30/2019

Trifluoperazine, a trifluoro-methyl phenothiazine derivative, is widely used in the management of schizophrenia and related psychotic disorders. We studied the effects of trifluoperazine on Kv4.3 currents expressed in CHO cells using the whole-cell patch-clamp technique. Trifluoperazine blocked ...detailed

The antipsychotic Trifluoperazine (cas 117-89-5) reduces marble-burying behavior in mice via D2 and 5-HT2A receptors: Implications for obsessive–compulsive disorder08/29/2019

Trifluoperazine, a typical antipsychotic drug, not only antagonizes dopamine D2 receptors but also enhances serotonin 5-HT2 receptor-mediated behavior. Moreover, trifluoperazine suppresses human purinergic receptor P2X7 responses and calmodulin. However, the effect of trifluoperazine on marble-b...detailed

A chemical screen identifies Trifluoperazine (cas 117-89-5) as an inhibitor of glioblastoma growth08/28/2019

Glioblastoma (GBM) is regarded as the most common malignant brain tumor but treatment options are limited. Thus, there is an unmet clinical need for compounds and corresponding targets that could inhibit GBM growth. We screened a library of 80 dopaminergic ligands with the aim of identifying com...detailed

Reprint of: A chemical screen identifies Trifluoperazine (cas 117-89-5) as an inhibitor of glioblastoma growth08/27/2019

Glioblastoma (GBM) is regarded as the most common malignant brain tumor but treatment options are limited. Thus, there is an unmet clinical need for compounds and corresponding targets that could inhibit GBM growth. We screened a library of 80 dopaminergic ligands with the aim of identifying com...detailed

Research paperRepositioning of the antipsychotic Trifluoperazine (cas 117-89-5): Synthesis, biological evaluation and in silico study of Trifluoperazine (cas 117-89-5) analogs as anti-glioblastoma agents08/26/2019

Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested. However, trifluoperazine did not increase the survival time in mice models of glioblastoma. In attempt to identify an effective trifluoperazine analog,...detailed

117-89-5Relevant articles and documents

Kuppuswamy et al.

, p. 652 (1974)

A mechanistic study on the disproportionation and oxidative degradation of phenothiazine derivatives by manganese(III) complexes in phosphate acidic media

Wisniewska, Joanna,Rzesnicki, Pawel,Topolski, Adrian

scheme or table, p. 767 - 774 (2012/07/01)

The oxidative degradation of phenothiazine derivatives (PTZ) by manganese(III) was studied in the presence of a large excess of manganese(III)-pyrophosphate (P2O7 2-), phosphate (PO4 3-), and H+ ions using UV-vis. spectroscopy. The first irreversible step is a fast reaction between phenothiazine and manganese pyrophosphate leading to the complete conversion to a stable phenothiazine radical. In the second step, the cation radical is oxidized by manganese to a dication, which subsequently hydrolyzes to phenothiazine 5-oxide. The reaction rate is controlled by the coordination and stability of manganese(III) ion influenced by the reduction potential of these ions and their strong ability to oxidize many reducing agents. The cation radical might also be transformed to the final product in another competing reaction. The final product, phenothiazine 5-oxide, is also formed via a disproportionation reaction. The kinetics of the second step of the oxidative degradation could be studied in acidic phosphate media due to the large difference in the rates of the first and further processes. Linear dependences of the pseudo-first-order rate constants (k obs) on [Mn III] with a significant non-zero intercept were established for the degradation of phenothiazine radicals. The rate is dependent on [H+] and independent of [PTZ] within the excess concentration range of the manganese(III) complexes used in the isolation method. The kinetics of the disproportionation of the phenothiazine radical have been studied independently from the further oxidative degradation process in acidic sulphate media. The rate is inversely dependent on [PTZ+.], dependent on [H+], and increases slightly with decreasing H+ concentration. Mechanistic consequences of all these results are discussed.

Stability of some phenothiazine free radicals.

Levy,Tozer,Tuck,Loveland

, p. 898 - 905 (2007/10/10)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 117-89-5